NOVAVAX, INC. Form 8-K (June 14, 2020)

Summary

Current report on Form 8-K of Novavax, Inc. dated June 14, 2020, reporting under Item 5.02, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. The report states that on June 14, 2020 the Board of Directors appointed David M. Mott as a Class II director effective June 16, 2020, with a term expiring at the 2021 annual meeting of stockholders. Mott will receive an annual retainer of $40,000 for Board service and $7,500 for Compensation Committee service, and was granted a stock option award of 8,000 shares. Before joining, Mott agreed to buy 32,916 shares directly from the company at $45.57 per share, bringing total ownership to 64,961 shares. The press release dated June 16, 2020 is Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): June 14, 2020

NOVAVAX, INC.

(Exact name of registrant as specified
in charter)

Delaware | 0-26770 | 22-2816046
(State
 or Other Jurisdiction of
 Incorporation) | (Commission File Number) | (I.R.S.
 Employer Identification
 No.)

21 Firstfield Road

Gaithersburg, Maryland 20878

(Address
of Principal Executive Offices, including Zip Code)

(240) 268-2000

(Registrant’s
telephone number, including area code)

(Former name or former
address, if changed since last report.)

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $0.01 per share | NVAX | The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):

¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. | Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment
of Director David M. Mott

On June 14, 2020,
the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) appointed David M. Mott to the Company’s
Board, effective on June 16, 2020. Mr. Mott will serve as a Class II director and his term will expire at the Company’s 2021
annual meeting of stockholders. The Board also appointed Mr. Mott to serve on the Board’s Compensation Committee. Mr. Mott
will receive an annual retainer of $40,000 for his service on the Board and an annual retainer of $7,500 for his service on the
Compensation Committee. Mr. Mott was granted a stock option award of 8,000 shares of Company common stock under the Company’s
Amended and Restated 2015 Stock Incentive Plan, as amended.

There is no arrangement
or understanding between Mr. Mott and any other person pursuant to which Mr. Mott was selected as a director. The Board has affirmatively
determined that Mr. Mott is independent. In advance of joining the Board, Mr. Mott agreed to purchase 32,916 shares of Company
common stock directly from the Company in a sale exempt from the registration requirements of the Securities Act of 1933, as amended,
pursuant Section 4(a)(2) thereunder, at a purchase price of $45.57 per share, resulting in Mr. Mott’s total ownership of
64,961 shares of Company common stock following such purchase. He has no other material direct or indirect interest in a related
party transaction that requires disclosure.

Mr. Mott and the
Company have entered into an indemnification agreement (the “Indemnification Agreement”) which will provide indemnification
protection for Mr. Mott in connection with his service as a director of the Company. The Indemnification Agreement is substantially
similar to the form filed as Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009,
filed on March 16, 2010 and incorporated herein by reference.

On June 16, 2020,
the Company issued a press release announcing Mr. Mott’s appointment to the Board. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. | Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description
10.1 | Form of Indemnification Agreement entered into between the Company and its directors and officers (Incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 000-26770), filed on March 16, 2010).
99.1 | Press release of the Company, dated June 16, 2020, regarding the appointment of David M. Mott to the Company’s Board of Directors.

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

Novavax, Inc.
Date: June 18, 2020 | By: | /s/ John A. Herrmann III
Name: | John A. Herrmann III
Title: | Senior Vice President, General Counsel and Corporate Secretary

File and source

File

SEC_NVAX_8-K_filed2020-06-18_0001104659-20-074714.htm

Size

24,096 bytes

SHA-256

b718dc24da47e4526be6c00e7bcc1e9110ccb84a3a7cfd1d6303749083a942ed

Our copy

SEC_NVAX_8-K_filed2020-06-18_0001104659-20-074714.htm

Original

www.sec.gov